WEKO3
アイテム
Positron Emission Tomography Myocardial Perfusion Imaging Tracer Choice for Assessment of Myocardial Blood Flow
https://repo.qst.go.jp/records/77173
https://repo.qst.go.jp/records/77173b63e0b4f-85f9-4bef-8531-6749d090d582
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-10-18 | |||||
タイトル | ||||||
タイトル | Positron Emission Tomography Myocardial Perfusion Imaging Tracer Choice for Assessment of Myocardial Blood Flow | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Tamaki, Nagara
× Tamaki, Nagara× Yoshinaga, Keiichiro× Keiichiro, Yoshinaga |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Myocardial perfusion imaging (MPI) using positron emission tomography (PET) has high diagnostic accuracy and prognostic value in patients with known or suspected coronary artery disease (CAD). In addition, PET MPI can be used to quantify global left ventricle (LV) and regional LV myocardial blood flow (MBF) and myocardial flow reserve (MFR). Currently, there are four major PET perfusion tracers: 82rubidium, 13N-ammonia, 15O-water, and 18F-flurpiridaz. The characteristics of each tracer have been described and fully compared. Given increasing clinical needs for accurate MBF and MFR measurements, the use of PET MPI should be expanded in clinical settings in the near future. | |||||
書誌情報 |
Annals of Nuclear Cardiology 巻 5, 号 1, p. 50-52, 発行日 2019-08 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 2424-1741 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.17996/anc.19-00107 | |||||
関連サイト | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://www.jstage.jst.go.jp/article/anc/5/1/5_19-00107/_pdf/-char/en |